(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 7.49% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.17%.
Neogenomics's revenue in 2025 is $689,189,000.On average, 6 Wall Street analysts forecast NEO's revenue for 2025 to be $93,303,910,170, with the lowest NEO revenue forecast at $93,073,197,151, and the highest NEO revenue forecast at $93,716,506,689. On average, 6 Wall Street analysts forecast NEO's revenue for 2026 to be $102,802,414,246, with the lowest NEO revenue forecast at $101,857,343,447, and the highest NEO revenue forecast at $104,697,981,345.
In 2027, NEO is forecast to generate $112,490,681,717 in revenue, with the lowest revenue forecast at $110,677,659,757 and the highest revenue forecast at $114,604,689,866.